The question heading into Tuesday is not whether Medtronic can hit consensus. It almost certainly will. The more interesting question is whether the Street has correctly priced what comes after.
Why This Stock Now
Medtronic reports financial results for its first quarter of fiscal year 2027, which ended July 31, 2026, on Tuesday, September 1, 2026. Analysts expect diluted EPS of $1.38, up 9.5% from $1.26 in the year-ago quarter. MDT has surpassed Wall Street’s EPS estimates in each of the past four quarters. That track record is relevant. Management has consistently guided low and delivered high, creating exactly the kind of earnings situation where the bar is beatable even when expectations have already moved up.
Needham raised its price target on Medtronic to $114 from $101 this week while maintaining a Buy rating. The firm expects Medtronic to beat consensus revenue and EPS estimates, citing new product launches, stable market growth, and management’s conservative guidance as supporting factors. Needham also expects the company to raise its full-year fiscal 2027 revenue and earnings guidance. A guidance raise on top of a beat would be the kind of double catalyst that moves a large-cap stock with sustained momentum rather than a single pop.
The Business
Medtronic is not the slow-growth medical device incumbent it was three years ago. Management has identified four generational growth drivers: its PFA platform for atrial fibrillation, Symplicity Spyral for hypertension, Altaviva for urinary incontinence, and the Hugo surgical robot. Each could ultimately deliver well over $1 billion in revenue, and each serves a large underpenetrated market.
The launches are real and moving fast. With 80% growth year-over-year, Cardiac Ablation Solutions was the company’s fastest-growing business in Q3 fiscal 2026, with PFA growing nearly 200% worldwide. Medtronic gained four points of share in the $13-plus billion electrophysiology market with its Affera platform and Sphere-9 catheter. On the robotics side, the Hugo RAS system received FDA clearance for urologic surgical procedures in December 2025 and is now in commercial use at leading U.S. hospitals, with 510(k) submissions filed for general surgery and gynecologic indications as well.
Why Wall Street Is Paying Attention
Needham noted that Medtronic is in the early stages of a strong product cycle, led by the Affera PFA system, Symplicity renal denervation system, and Hugo robot. That framing matters because the market has only begun to price these assets. Tariffs remain a headwind, modeled at roughly $250 million for fiscal 2027, reducing gross margin by approximately 20 basis points on a full-year basis. Management already told investors this. The tariff drag is known and partially baked in, which means any better-than-feared pass-through commentary Tuesday could shift sentiment further.
The macro environment is also cooperating. Defensives have outperformed through August as investors reassess rate risk, and Medtronic’s forward dividend yield of approximately 3.3% positions it as a defensive equity suitable for investors seeking stability and income during periods of market volatility. The company recently announced a quarterly cash dividend of $0.72 per share. That combination of yield and accelerating revenue growth is uncommon in large-cap healthcare right now.
What Could Go Wrong
The risks are real and worth sizing. Management guided Q1 EPS of $1.38 to $1.40, and the upper end of that range benefits by roughly 600 to 700 basis points from an extra selling week. Strip that out and the organic comparison is tougher than the headline suggests. Any softness in procedural volumes or hospital capital spending on Hugo placements could trim the beat.
In Q4 fiscal 2026, Medtronic’s non-GAAP operating margin declined 230 basis points year-over-year. Margin compression has been the persistent frustration for investors who believe in the product story but worry about profitability. Tariff commentary Tuesday will be parsed closely. The company provided full-year EPS guidance of $5.90 to $6.00, a gap management needs to close with forward raises to satisfy the bulls.
The Bottom Line
Medtronic is the clearest quality-and-catalyst combination in large-cap healthcare entering September. The company delivered $36.4 billion in fiscal 2026 revenue, its strongest annual top-line growth in a decade, driven by strength in Cardiovascular and ablation solutions that outpaced market rates. The product cycle is not hypothetical anymore. Affera is gaining share in a $13 billion market, Hugo has FDA clearance and is expanding indications, and Symplicity is building a reimbursement foundation targeting millions of Americans with uncontrolled hypertension.
Tuesday’s report is the first meaningful medtech read of the new month and the cleanest single-company window into device volumes and tariff dynamics. With four consecutive beats behind it and Needham arguing guidance has been systematically conservative, the risk-reward heading into the print favors the long side. The call is MDT.
